EFFECT OF COMBINED SUPPLEMENTATION OF MAGNESIUM-OXIDE AND PYRIDOXINE IN CALCIUM-OXALATE STONE FORMERS

被引:23
|
作者
RATTAN, V
SIDHU, H
VAIDYANATHAN, S
THIND, SK
NATH, R
机构
[1] POSTGRAD INST MED EDUC & RES,DEPT BIOCHEM,CHANDIGARH 160012,INDIA
[2] POSTGRAD INST MED EDUC & RES,DEPT UROL,CHANDIGARH 160012,INDIA
来源
UROLOGICAL RESEARCH | 1994年 / 22卷 / 03期
关键词
MAGNESIUM OXIDE; PYRIDOXINE; CALCIUM OXALATE; UROLITHIASIS; THERAPEUTIC EFFECT;
D O I
10.1007/BF00571844
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A combined supplement of magnesium oxide (300 mg/day) and pyridoxine . HCl (10 mg/day) was given p.o. to 16 recurrent calcium oxalate (CaOx) stone formers, and its therapeutic efficacy was biochemically evaluated by measuring various parameters of blood (Na, K, Mg, urea, creatinine, calcium, phosphate, uric acid, alanine transaminase, aspartate transaminase and alkaline phosphatase) and urine (volume, pH, creatinine, Na, K, Mg, uric acid, calcium, phosphate, oxalate and citrate) at 0, 30, 60, 90 and 120 days of treatment. Serum Mg significantly (P<0.01) increased after 30 days of treatment and remained constant thereafter while other blood parameters were unaltered. Combined treatment led to a significant increase in the urinary excretion of Mg and citrate over pretreatment values while oxalate excretion showed a gradual and significant decline during the therapy. The results confirmed the efficacy of MgO-pyridoxine supplementation in terms of changes in urinary excretion of lithogenic and inhibitory components, leading to a significant (P<0.01) decrease in CaOx risk index from 0.09 +/- 0.04 at 0 day to 0.05 +/- 0.02 after 120 days of treatment.
引用
收藏
页码:161 / 165
页数:5
相关论文
共 50 条
  • [31] STUDIES ON UROLITHIASIS - CRYSTAL AGGREGATION IN CALCIUM-OXALATE STONE FORMERS
    SUZUKI, K
    JAPANESE JOURNAL OF UROLOGY, 1981, 72 (07): : 842 - 855
  • [32] INHIBITOR OF CALCIUM-OXALATE CRYSTALLIZATION IN URINE OF NORMALS AND STONE FORMERS
    TEOTIA, M
    TEOTIA, SPS
    INDIAN JOURNAL OF MEDICAL RESEARCH, 1975, 63 (08) : 1209 - 1216
  • [33] MAGNESIUM THERAPY IN CALCIUM-OXALATE STONE PATIENTS
    JARRAR, K
    GRAEF, V
    BOEDECKER, RH
    UROLOGICAL RESEARCH, 1988, 16 (03): : 242 - 242
  • [34] Effect of milk supplementation on stone risk in normocalciuric calcium oxalate stone formers.
    Massey, LK
    KynastGales, SA
    FASEB JOURNAL, 1996, 10 (03): : 4550 - 4550
  • [35] Effect of milk supplementation on stone risk in normocalciuric calcium oxalate stone formers.
    Massey, LK
    KynastGales, SA
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : M771 - M771
  • [36] URINE COMPOSITION IN CALCIUM-OXALATE STONE FORMERS DURING TREATMENT WITH ALKALI
    TISELIUS, HG
    UROLOGICAL RESEARCH, 1984, 12 (01): : 45 - 45
  • [37] NUCLEATION AND GROWTH OF BRUSHITE AND CALCIUM-OXALATE IN URINE OF STONE-FORMERS
    PAK, CYC
    HOLT, K
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1976, 25 (06): : 665 - 673
  • [38] EFFECT OF MAGNESIUM ON CALCIUM-OXALATE UROLITHIASIS
    SU, CJ
    SHEVOCK, PN
    KHAN, SR
    HACKETT, RL
    JOURNAL OF UROLOGY, 1991, 145 (05): : 1092 - 1095
  • [39] DIFFERENCES IN SEX AND ACIDIFICATION IN IDIOPATHIC CALCIUM-PHOSPHATE AND CALCIUM-OXALATE STONE FORMERS
    GAULT, H
    PARFREY, P
    ROBERTSON, W
    PAUL, M
    HARNETT, J
    DOW, D
    PRABHAKARAN, V
    CHAFE, L
    MORGAN, J
    GRIFFITHS, S
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1987, 10 (04): : B104 - B104
  • [40] Monitoring of the treatment of calcium-oxalate stone formers with the Bonn-Risk-Index
    Laube, N
    Schmidt, M
    Hesse, A
    UROLOGE A, 2003, 42 (02): : 243 - +